NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Update

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 35,200 shares, a drop of 43.0% from the February 29th total of 61,800 shares. Based on an average daily volume of 491,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are sold short.

NLS Pharmaceutics Trading Up 3.0 %

Shares of NASDAQ:NLSP traded up $0.00 during trading on Thursday, reaching $0.17. The stock had a trading volume of 164,701 shares, compared to its average volume of 518,683. NLS Pharmaceutics has a 52 week low of $0.14 and a 52 week high of $1.60. The stock has a fifty day simple moving average of $0.39 and a two-hundred day simple moving average of $0.53.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in NLSP. Susquehanna International Group LLP bought a new position in NLS Pharmaceutics during the first quarter valued at about $35,000. Two Sigma Securities LLC bought a new position in NLS Pharmaceutics during the second quarter valued at about $41,000. Renaissance Technologies LLC increased its stake in NLS Pharmaceutics by 58.9% during the first quarter. Renaissance Technologies LLC now owns 32,100 shares of the company’s stock valued at $49,000 after acquiring an additional 11,900 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in NLS Pharmaceutics by 16.2% during the second quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the company’s stock valued at $440,000 after acquiring an additional 55,911 shares during the period.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).